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1. introduction 
Human platelets contain an enzyme, thromboxane 
synthase, which converts the prostaglandin (PG) 
endoperoxide PGHs to thromboxane As [ 1,2]. The 
same enzyme also forms IZhydroxy-5,8,10-hepta- 
decatrienoic acid (HHT) from PGHs [3]. When PGHr 
was incubated with partially purified platelet enzyme, 
only small amounts of thrombox~e Br tiere formed. 
The major product was 12-hydrox~8,10-heptade~- 
dienoic acid (HHD) [3]. 
Enzyme inhibitors and substrate competition experi- 
ments have now shown that the conversion of PGHr 
to HHD is catalyzed by thromboxane synthase. The 
lack of a As -double bond in PGHr , seems to preclude 
the formation of thromboxane Ar. To further inves- 
tigate this point, a positional isomer of PGHs with 
the cis double bond at A4 was prepared. This sub- 
strate was converted to A4-HHD but not appreciably 
to a thrombox~e. Therefore, the enzyme appears 
to specific&y require a A5-double bond in order to 
isomerize prostaglandin endoperoxides to throm- 
boxanes. 
Abbreviations: BSTFA, bis(trimethylsilyl) trifluoroacetamide; 
DEAE, diethylaminoethyl; HHD, 12-hydroxy-8,l O-heptade- 
cadienoic acid; HHT, 12-hydroxy-5,8,10-heptadecatrienoic 
acid; HPNT, 12-hydroperoxy-5,8,10-heptadecatrienoic ac d; 
HFI’XA,, 15-hydroperoxythromboxane A,; L;8027,2-iso- 
propyl-3-nicotinyhndole; PG. prostaglandin; SD, standard 
deviation;TLC, thin-layer chromato~aphy;TX, thromboxane 
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2. Materials and methods 
Human platelet microsomes, [ 1 -r4C]PGHI (spec. 
act. 0.34 Ci/mol) and [l-r4C]PGH2 (spec. act. 1 Ci/ 
mol) were prepared as in [I]. 4,8,11,14-Eicosate- 
traynoic acid was a generous gift from Drs Nugteren 
and van Dorp, Unilever Research, Vlaardingen, The 
Netherl~ds. Lindlar catalyst was purchased from 
Fluka AC, Buchs SC;, Switzerland. 
2.1.4,&I I, 14-(all cis)-f 3HsjEicosaretraenoic acid 
To a solution of 15 mg 4,8,11,14eicosatetraynoic 
acid in 0.75 ml methanol, 3 mg Lindlar catalyst and 
3 mg quinoline was added. The acid was reduced 
with Hz at room temperature for 80 mm with vigor- 
ous stirring. 
Tritium-labeled 4,8,11,14eicosatetraenoic acid 
was prepared in a similar way using 3H2 instead of 
‘Hz. 
Part of the crude products from these two reduc- 
tions were pooled, water was added and the mixture 
acidified to pH 3. After extraction with diethyl ether 
the solvent was evaporated under reduced pressure 
and the residue was dissolved in methanol/water/ 
acetic acid (85 : 15 :O.O 1, v/v/v). This material was 
purified by reversed phase high pressure liquid chro- 
matography (HPLC), first with methanol/water/acetic 
acid (85 : 15 :O.Ol , v/v/v) as solvent system, and in a 
second run with methanollwaterfacetic acid 
(80:20:0.01, v/v/v}. 
2.2. cis-A4-f4,S,8,9,11,12,14,15-3Hs/~H~ 
The labeled eicosatetraenoic a id (5 mg, 3.58 Ci/ 
mol) was incubated with sheep vesicular gland micro- 
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somes as in [4]. The products were chromatographed 
on silicic acid. A major radioactive compound eluted 
in the fraction reported to elute PGHz [4]. 
Confirmation of the structure was made by the 
following experiments. The product cochromato- 
graphed with authentic PGHz on silica gel G (TLC) 
with ethyl acetate/trimethyl pentane/acetic acid 
(SO:SO:O.S, v/v/v) as solvent system. Incubation of 
the product with 0.1 M phosphate buffer (pH 7.4) 
for 30 min at room temperature yielded a com- 
pound which cochromatographed with authentic 
PGEz on TLC (solvent diethyl ether~methanol 
(49: 1, v/v)). Reduction of the material with stan- 
nous chloride produced a substance which cochro- 
matographed with PGF2, on TLC in the same sol- 
vent system. 
2.3. Inhibition experiments 
Human platelet microsomes were preincubated for 
15 s with various concentrations of either L-8027 
(2-isopropyl-3-nicotinyl-indole) or imidazole, two 
thrombox~e synthase in~bitors [S--7]. f 1-‘4C]PGH1 
or [l- 14C]PGHz was added and the incubation was 
continued for 60 s at 24°C. The substrate concentra- 
tions were 124 PM and 143 PM, respectively. The 
reaction was stopped by addition of cold (-78°C) 
citric acid in ether/methanol [7]. The reaction mix. 
tures were analyzed for 12-hydroxy-8,1 O-hepta- 
decadienoic acid (HHD) or 12-hydroxy-5,8,10- 
heptadecatrienoic acid (HHT) [3]. 
2.4. Variations of pH in incubation medium 
PGH2 was incubated with platelet microsomes, 
solubilized microsomes and solubilized microsomes 
which had been further purified by DEAE-cellulose 
chromatography [l] in buffers of varying pH. The 
following buffers were used: pH < 6, Na-acetate; 
6 < pH < 8, K-phosphate; pH > 8, Tris-HCl. Final 
buffer concentrations were 80 mM. After 60 s at 
24°C the incubation mixtures were analyzed for 
HHT and TXB2. 
2 .S . Competition experiments 
A constant amount (5.65 pg) of [ I-‘4C]PGH~ was 
incubated with 200 ~1 human platelet microsomes 
and varying amounts of unlabeled PGHz for 1 min at 
24’C. Percent conversion of PGHl to HHD was 
measured. 
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2.6. Incubations with PGH,, cis-A4-PGH1, PGGz and 
PGH, 
Human platelet microsomes (200 ~1) were incubated 
for 1 min at 24’C with [1-‘4C]PGH1,cis A4-[3Hs]PGHl 
or [ 1-14C]PGHz (124 PM, 100 /IM and 143 ,uM, 
respectively). [ 1-‘4C]PGH2 was incubated under the 
same conditions with DEAE-cellulose fractionated 
solubilized enzyme [I]. After acidification and 
extraction with ether, thromboxanes and C-17 
hydroxy acids were analyzed by thin-layer chroma- 
tography as in 131. A series of incubations of [ l-14C]- 
PGGz and [ 1 -14C]PGHz were performed with DEAE- 
cellulose purified thromboxane synthase to generate 
thromboxane AZ and 1 S-hydroperoxy thromboxane 
AZ [4] and to determine the ratios of C-17 acids to 
thromboxanes formed, 
3. Results 
3.1. In~iibitiot~ of HHD fo~ation 
Dose-inhibition curves for the conversion of PGH, 
and PGH:! to HHD and HHT by human platelet micro- 
somes are shown in fig-l. Both endoperoxides were 
converted to the corresponding C-17 acids when 
inhibitor was absent. When the microsomes were 
boiled prior t,o incubation, 5% of the endoperoxides 
were converted to the C- 17 acids. The non-enzymatic 
decomposition of endoperoxides to C-l 7 acids has 
been corrected for in fig. 1. 
Figure 2 shows the effect of unlabeled PGHz on 
the conversion of [ I-‘4C]PGHI to HHD. As the ratio 
of PGHz to PGHl increases the production of HI-ID 
decreases linearly. 
3 2. Ratios of C-I 7 acid to thromboxane formation: 
Effec Is of pH and ionic strength 
When PGH1 was incubated with platelet micro- 
somes, the ratio of HHD to TXBl in the ether extract 
was about 40.PGHz was incubated with DEAE-purified 
thromboxane synthase in a series of experiments. The 
mean ratio of HHT to TXI& was 2.3 f 0.05 (t SD, 
n= 17). Variations in pH from 5-8 did not affect 
enzyme activity markedfy. At pH > 8 the activity 
usually decreased. The ratio of HHT to TXBz formed 
in these experiments was relatively constant. 
Soiubilized platelet microsomes were incubated 
with PGHz in the presence of varying concentrations 
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Fig.1. Dose-inhibition curves for the conversion of PGH, 
and PGH, to HHD and HHT by human platelet microsomes: 
(0) L-8027; (Q) imidazole. 
of NaCl. At < 0.5 M no effect on enzyme activity or 
on the ratio of HHT to TXBz in ether extracts was 
observed. 
When PGGz was incubated with DEAE-purified 
1 
1 2 3 
PGH2/ PGHl 
Fig.2. Competition between [ I-‘%]PGH, and unlabeled PGH, 
for human platelet thromboxane synthase. 
thromboxane synthase a mean ratio of 12-hydro- 
peroxy-5,8,10-heptadecatrienoic acid to 15hydro- 
peroxy thromboxane Bs (cf. [4]) was 1.6 f: 0.04 
(k SD, n=15). 
3.3. Product formed from cis-A4-PGHr 
cis-A4-PGHr was synthesized from 4,8,11,14- 
eicosatetraynoic acid as outlined in fig.3. Incubations 
of this endoperoxide with human platelet microsomes 
yielded a product which cochromatographed with 
authentic HHT on TLC. This material was derivatized 
with diazomethane followed by BSTFA. Analyses by 
gas-liquid chromatography-mass pectrometry showed 
a C-value of 19.35 on 1% OV-1 and major ions at 
m/e 366 (M), 351 (M-15, loss of CHs), 335 (M-31, 
loss of .OCHs), 298,295 (M-71, loss of -(CH,).,CH,), 
276 (M-90, loss of (CH&SiOH), 239,225 (M-141, 
loss of CH2-CH2-CH=CH-(CH&-COOCHs), 205 
(M-71-90), and 173. 
These data suggest hat the product is a 12-hydroxy- 
heptadecatrienoic acid (cf. [S]). The ion at m/e 239 is 
probably formed by cleavage between C-6 and C-7 
and charge retention on the C-7 to C-17 fragment. 
The ion, which is absent from the mass spectrum of 












Fig.3. Synthesis of cis-A’-[ ‘H,]PGH,. I: 4,8,11,14-(allcis)- 
[ ‘H,]eicosatetraenoic acid; II: cis-A4-[ ‘H,]PGH,. 
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Table 1 
Conversion of endoperoxides by thromboxane synthase 
September 1979 
Conversion to Conversion to C-l 7 acid/ 
C-l 7 acid (%) thromboxane (%) thromboxane 
[ I-“‘C]PGH, 66.5 1.6 41.6 
A4-[4,5,8,9,~l,12,14,15-3H,]PGH, 89.5a 2.2b 40.7 
[1-‘4C]PGH2 49.0 23.4 2.1 
a Corrected for loss of 2 tritium atoms in malondialdehyde 
b Radioactive material cochromatographing with unlabeled TXB, 
HHT methyl ester, trimethylsilyl ether, suggests the 
occurrence of a A4-double bond in the present prod- 
uct (A4-HHD). 
The ratios of C-17 acids to thromboxanes formed 
from PGHr, cis-A4-PGHr and PGHa are summarized 
in table 1. 
4. Discussion 
HHT and thromboxane Bz are the principal metab- 
elites of arachidonic acid, formed via the cyclooxy- 
genase pathway in human platelets 181. Both com- 
pounds arise enzymatic~ly from PGH2 in reactions 
catalyzed by thromboxane synthase [3]. A common 
intermediate in the transformations has been pro- 
posed [3]. 





(HPHT 1 TXA2 
( HPTXA2 ) 
Br by partially purified thromboxane synthase. How- 
ever, it is transformed to the C-17 acid HHD [3]. 
This reaction was inhibited by L-8027 and imidazole 
(fig.1). The dose-inhibition curves were similar to 
those obtained when the conversion of PGHz to HHT 
was determined (fig. 1). Furthermore, unlabeled PGH? 
suppressed the formation of HHD from PGHr (frg.2). 
These data suggest hat thrombox~e synthase con- 
verts PGHr to HHD and PGHz to thromboxane AZ 
and HHT. The apparent dual catalysis may be 
explained if the enzyme can only perform an 
initial step of the isomerase reaction with PGHr 
as substrate. This initial step may involve protona- 
tion of the oxygen atom at C-9 as proposed earlier 
for PGHz [3]. The charged intermediate formed 
from PGHa is converted by further action of the 
enzyme to thromboxane A*. Alternatively, the inter- 
mediates formed from either endoperoxide may 
A4 -PGH, PGH, 
Ah-HHD HHD 
Pig.4. Transformations of endoperoxides by thromboxane synthase: HPHT, 12-hydroperoxy-.5,8,10-heptadecatrienoic acid (t); 
HPTXA,, 15hydroperoxy thromboxane A, (t); R,, -(CH,)$OOH; R,, -(CH,),CH,; R,, -(CH,),COOH. 
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rearrange to the C-17 acids HHD and HHT plus was supported by a grant from the Swedish Medical 
malondialdehyde. Research Council (project 03X-2 17). 
Experiments with cis-A4-PGH, showed that this 
endoperoxide istransformed predominantly to 
A4-HHD. The ratio of C-17 acid to thrombox~e 
was quite similar to that obtained using PGHl as 
substrate (table 1). This suggests a specific require- 
ment of a As-double bond in the endoperoxide sub- 
strate to allow isomerization to thromboxanes. 
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